You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

Viloxazine hydrochloride - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for viloxazine hydrochloride and what is the scope of patent protection?

Viloxazine hydrochloride is the generic ingredient in one branded drug marketed by Supernus Pharms and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Viloxazine hydrochloride has twenty-one patent family members in seven countries.

One supplier is listed for this compound.

Summary for viloxazine hydrochloride
International Patents:21
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 89
Clinical Trials: 12
Patent Applications: 272
What excipients (inactive ingredients) are in viloxazine hydrochloride?viloxazine hydrochloride excipients list
DailyMed Link:viloxazine hydrochloride at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for viloxazine hydrochloride
Generic Entry Date for viloxazine hydrochloride*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE, EXTENDED RELEASE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for viloxazine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
ApnimedPhase 2
Supernus Pharmaceuticals, Inc.Phase 4
Supernus Pharmaceuticals, Inc.Phase 3

See all viloxazine hydrochloride clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for viloxazine hydrochloride

US Patents and Regulatory Information for viloxazine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Supernus Pharms QELBREE viloxazine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 211964-001 Apr 2, 2021 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Supernus Pharms QELBREE viloxazine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 211964-001 Apr 2, 2021 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Supernus Pharms QELBREE viloxazine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 211964-002 Apr 2, 2021 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Supernus Pharms QELBREE viloxazine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 211964-001 Apr 2, 2021 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for viloxazine hydrochloride

Country Patent Number Title Estimated Expiration
Spain 2459322 ⤷  Sign Up
Australia 2020233746 Modified release formulations of viloxazine ⤷  Sign Up
Japan 2019123736 ビロキサジンの緩和放出製剤 (MODIFIED RELEASE FORMULATIONS OF VILOXAZINE) ⤷  Sign Up
European Patent Office 2812074 FORMULATIONS À LIBÉRATION MODIFIÉE DE VILOXAZINE (MODIFIED RELEASE FORMULATIONS OF VILOXAZINE) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.